Erasca, Inc. (ERAS) shares plummeted 5.39% during intraday trading on Friday, reflecting negative market sentiment following analyst actions.

The decline comes after Bank of America Securities analyst Alec Stranahan reiterated a Sell rating on the biopharmaceutical company and set a price target of just $2.00. This bearish outlook contrasts with some other analysts who have been more positive, creating uncertainty among investors.

Adding to the cautious environment, Erasca is scheduled to report its quarterly earnings later in the week, with analysts expecting a loss per share. The combination of a prominent sell-side firm maintaining a strongly negative stance ahead of earnings appears to have driven the stock's downward movement.